Alaunos reports Q3 net loss $8.9M; first objective response in TCR-T Library trial

Alaunos Therapeutics, Inc.

2022-Q3 EPS reported -$0.13 revenue$2,911,000

Q3 2022 net loss $8.9M ($0.04/sh) vs $22.7M ($0.11/sh) in Q3 2021; revenue $2.9M from darinaparsin milestone.
First patient with NSCLC achieved >50% tumor regression at 12 weeks with Sleeping Beauty TCR-T cells targeting KRAS G12D.
TCR-T cell persistence observed: ~30% of blood T-cells at 24 weeks in patient 1; manageable safety, no ICANS.
Manufacturing capacity doubled to produce two products simultaneously; IND amendment in 4Q22 to add two TCRs and switch to cryopreserved process (26 days vs 30).
Cash $37.8M plus restricted cash $13.9M; operating cash burn $6.1M in Q3 2022, down 36% YoY.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Alaunos Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $2.9 million.

Period: the third quarter ended September 30, 2022
Revenue: $2.9 million
Result: reported results

Exact text from the filing

Collaboration revenue was $2.9 million for the third quarter of 2022, compared to $0.4 million for the third quarter of 2021, an increase of 631%.

View on SEC.gov

Browse all earnings releases →

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-283649

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.